83.05
price up icon0.06%   0.05
after-market After Hours: 82.68 -0.37 -0.45%
loading
Astrazeneca PLC stock is traded at $83.05, with a volume of 5.07M. It is up +0.06% in the last 24 hours and up +4.79% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$83.00
Open:
$84.02
24h Volume:
5.07M
Relative Volume:
1.28
Market Cap:
$257.50B
Revenue:
$49.13B
Net Income/Loss:
$6.44B
P/E Ratio:
41.94
EPS:
1.98
Net Cash Flow:
$6.97B
1W Performance:
-5.22%
1M Performance:
+4.79%
6M Performance:
+27.24%
1Y Performance:
+23.96%
1-Day Range:
Value
$82.93
$84.30
1-Week Range:
Value
$82.46
$87.25
52-Week Range:
Value
$60.47
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-07-25
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
Sep 08, 2024

Morton Community Bank Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Sep 08, 2024
pulisher
Sep 06, 2024

AstraZeneca Unit Owes $130M In Chancery Scuttled-Drug Suit - Law360

Sep 06, 2024
pulisher
Sep 06, 2024

AstraZeneca rises Friday, outperforms market - MarketWatch

Sep 06, 2024
pulisher
Sep 06, 2024

As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider? - Yahoo Finance UK

Sep 06, 2024
pulisher
Sep 06, 2024

3 Market-Beating Stocks to Buy for Less Than $100 - The Motley Fool

Sep 06, 2024
pulisher
Sep 05, 2024

China detains AstraZeneca staff in data, drug-import probes - The Spokesman Review

Sep 05, 2024
pulisher
Sep 05, 2024

Trending tickers: NatWest, AstraZeneca, Shopify, Coinbase - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities - AOL

Sep 05, 2024
pulisher
Sep 05, 2024

AstraZeneca’s Alexion Hit With Damages Exceeding $130 Million - Bloomberg Law

Sep 05, 2024
pulisher
Sep 05, 2024

AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities - Yahoo Finance

Sep 05, 2024
pulisher
Sep 05, 2024

FDx Advisors Inc. Sells 6,044 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Sep 05, 2024
pulisher
Sep 05, 2024

AstraZeneca Believes Size Matters In Amyloidosis - Scrip

Sep 05, 2024
pulisher
Sep 05, 2024

AstraZeneca falls Thursday, underperforms market - MarketWatch

Sep 05, 2024
pulisher
Sep 05, 2024

China detains AstraZeneca staff in data, drug-import probes: Report - The New Indian Express

Sep 05, 2024
pulisher
Sep 05, 2024

AstraZeneca, a mega-cap growth stock that just got cheaper! - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

AstraZeneca slides after confirming five employees held by China police - Proactive Investors USA

Sep 05, 2024
pulisher
Sep 05, 2024

Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report - GlobeNewswire Inc.

Sep 05, 2024
pulisher
Sep 05, 2024

AstraZeneca slides after confirming five employees held by China police - Proactive Investors Australia

Sep 05, 2024
pulisher
Sep 05, 2024

Subscribe to read - Financial Times

Sep 05, 2024
pulisher
Sep 05, 2024

China detains AstraZeneca employees in illegal activities probe - Al Arabiya English

Sep 05, 2024
pulisher
Sep 05, 2024

China Detains AstraZeneca Staff in Data, Drug-Import Probes - Yahoo Finance

Sep 05, 2024
pulisher
Sep 05, 2024

China detains AstraZeneca staff in data, drug-import probes, Bloomberg News reports - Marketscreener.com

Sep 05, 2024
pulisher
Sep 05, 2024

China Detains AstraZeneca Staff in Data, Drug-Import Probes - BNN Bloomberg

Sep 05, 2024
pulisher
Sep 04, 2024

Trending tickers: AMD, Shell, AstraZeneca, HubSpot - Yahoo Finance UK

Sep 04, 2024
pulisher
Sep 04, 2024

AstraZeneca, Samsung Biologics Settle Soliris Biosimilar Lawsuit - Bloomberg Law

Sep 04, 2024
pulisher
Sep 04, 2024

AstraZeneca Looks To Clinical Trial Innovations To Help Meet Oncology Ambitions - Scrip

Sep 04, 2024
pulisher
Sep 04, 2024

Europe Breast Cancer Screening Market Forecast Report and Company Analysis 2024-2032 Featuring AstraZeneca, Novartis, Sanofi, Pfizer, Bayer, and GlaxoSmithKline - Yahoo Finance

Sep 04, 2024
pulisher
Sep 04, 2024

AstraZeneca in first COVID-19 vaccine deal with Chinese company - Yahoo News UK

Sep 04, 2024
pulisher
Sep 04, 2024

Cozad Asset Management Inc. Buys 8,400 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Sep 04, 2024
pulisher
Sep 03, 2024

Is AstraZeneca PLC (AZN) the Best Cancer Stock to Buy Now? - Yahoo Finance

Sep 03, 2024
pulisher
Sep 03, 2024

Several Reasons for the Outperformance of Astrazeneca Plc (AZN) - MSN

Sep 03, 2024
pulisher
Sep 03, 2024

AstraZeneca PLC ADR falls Tuesday, still outperforms market - MarketWatch

Sep 03, 2024
pulisher
Sep 03, 2024

Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs - Benzinga

Sep 03, 2024
pulisher
Sep 03, 2024

AstraZeneca falls Tuesday, still outperforms market - MarketWatch

Sep 03, 2024
pulisher
Sep 03, 2024

Naviter Wealth LLC Increases Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Sep 03, 2024
pulisher
Sep 03, 2024

AstraZeneca reports total voting rights as of August end - Investing.com

Sep 03, 2024
pulisher
Sep 03, 2024

AstraZeneca: to present its advances in oncology - Marketscreener.com

Sep 03, 2024
pulisher
Sep 03, 2024

Trending tickers: latest investor updates on Gold, Ryanair, Nvidia and AstraZeneca - Yahoo Finance UK

Sep 03, 2024
pulisher
Sep 03, 2024

Several Reasons for the Outperformance of Astrazeneca Plc (AZN) - Yahoo Finance

Sep 03, 2024
pulisher
Sep 02, 2024

AstraZeneca PLC (AZN): A Good 52-Week High Stock to Buy According to Short Sellers - MSN

Sep 02, 2024
pulisher
Sep 02, 2024

AstraZeneca PLC (AZN): A Good 52-Week High Stock to Buy According to Short Sellers - Yahoo Finance

Sep 02, 2024
pulisher
Sep 02, 2024

Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030 - GlobeNewswire Inc.

Sep 02, 2024
pulisher
Sep 02, 2024

AstraZeneca rises Monday, outperforms market - MarketWatch

Sep 02, 2024
pulisher
Sep 02, 2024

AstraZeneca Shares and Voting Rights Update - TipRanks

Sep 02, 2024
pulisher
Sep 02, 2024

Here’s why H1 results could boost the AstraZeneca share price - Yahoo Finance UK

Sep 02, 2024
pulisher
Sep 02, 2024

AstraZeneca (LON:AZN) Reaches New 12-Month High at $13,372.00 - MarketBeat

Sep 02, 2024
pulisher
Sep 02, 2024

FY2025 EPS Estimates for AstraZeneca PLC (NASDAQ:AZN) Boosted by Analyst - MarketBeat

Sep 02, 2024
pulisher
Sep 01, 2024

AstraZeneca hits £200bn as its share price soars. Can I afford to miss out? - Yahoo Finance UK

Sep 01, 2024
pulisher
Aug 31, 2024

Barlow Wealth Partners Inc. Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Aug 31, 2024
pulisher
Aug 31, 2024

As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider? - MSN

Aug 31, 2024
pulisher
Aug 31, 2024

As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider? - Motley Fool UK

Aug 31, 2024

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):